Glibenclamide in cerebral ischemia and stroke

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Biology

Background:

• The Sur1-Trpm4 channel is crucial in focal cerebral ischemia, contributing to edema and cell death.
• Channel upregulation occurs in neurovascular unit cells post-ischemia, driving microvascular dysfunction.
• Channel activation is a key mechanism for cytotoxic edema and necrotic cell death.

Purpose of the Study:

• To review the role of glibenclamide in focal cerebral ischemia and stroke.
• To evaluate glibenclamide's efficacy in preclinical stroke models and retrospective clinical studies.
• To assess the translational potential of glibenclamide for ischemic stroke patients.

Main Methods:

• Review of basic science, preclinical experiments in rat stroke models, and retrospective clinical studies.
• Analysis of glibenclamide's effects on brain swelling, infarct volume, neurological function, edema, mortality, and hemorrhagic transformation.
• Comparison of preclinical findings with Stroke Therapy Academic Industry Roundtable (STAIR) recommendations.

Main Results:

• Glibenclamide reduced brain swelling, infarct volume, and improved neurological function in non-lethal stroke models.
• In lethal stroke models, glibenclamide decreased edema, swelling, and mortality.
• Retrospective studies indicated better outcomes and reduced hemorrhagic transformation in stroke patients on sulfonylureas.

Conclusions:

• Glibenclamide effectively mitigates key pathological features of focal cerebral ischemia in preclinical models.
• Clinical data suggests a potential benefit of sulfonylurea drugs in stroke patients.
• Findings support a translational research program for glibenclamide in ischemic stroke treatment.